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Facile heterocyclic synthesis and antimicrobial activity of 
polysubstituted and condensed pyrazolopyranopyrimidine  
and pyrazolopyranotriazine derivatives
Reaction of 6-amino-3-methyl-4-(substituted phenyl)-1,4-
dihydropyrano[2,3-c]pyrazole-5-carbonitrile (1) with tri-
ethylorthoformate followed by treatment with hydrazine 
hydrate, formic acid, acetic acid, phenylisocyanate, ammo-
nium thiocyanate and formamide afforded the correspond-
ing pyranopyrimidine derivatives 2–6. Cyclocondensation 
of 1 with cyclohexanone afforded pyrazolopyranoquinoline 
7. One-pot process of diazotation and de-diazochlorination 
of 1 afforded pyrazolopyranotriazine derivative 8, which 
upon treatment with secondary amines afforded 9 and 10a–
c. Condensation of 2 with aromatic aldehyde gave the cor-
responding Schiff bases 11a,b, the oxidative cyclization of 
the hydrazone with appropriate oxidant afforded 11-(4 -fluo-
rophenyl))-2-(4-substituted phenyl)-10-methyl-8,11-dihydro-
pyrazolo-[4’,3’:5,6]pyrano[3,2-e][1,2,4]triazolo[1,5-c]pyrimi-
dines (12a,b). Structures of the synthesized compounds 
were confirmed by spectral data and elemental analysis. All 
synthesized compounds were evaluated for antibacterial 
and antifungal activities compared to norfloxacin and fluco-
nazole as standard drugs. Compounds 9, 10c, 12a and 15 
were found to be the most potent antibacterial agents, with 
activity equal to that of norfloxacin. On the other hand, 
compound 5 exhibited higher antifungal activity compared 
to fluconazole.
Keywords: pyrazolopyranopyrimidine, pyrazolopyranotri-
azine, pyrazolopyranoquinoline, antimicrobial activity
Antibiotic resistance, which results from inappropriate and irrational use of antimi-
crobial medicines, provides favorable conditions for resistant bacteria to emerge. This re-
sistance of pathogenic bacteria towards available antibiotics is rapidly becoming a major 
worldwide problem. Hence, the design of new compounds to deal with resistant bacteria 
has become one of the most important goals of antibacterial research today.
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In continuation of our study of the chemistry of heterocyclic b-enamino-carbonitrile 
(1) and the synthesis of fused pyrane ring systems of pharmacological importance (2), 
pyrane and its fused derivatives have attracted great interest owing to their antimicrobial 
(3–5), antiviral (6), antitumor (7), antiproliferactive (8), molluscicidal (9), and anti-inflam-
matory activities (10). Also, pyrane derivatives are well known antihistaminic agents (11). 
moreover, it has been noticed that introduction of an additional ring to the pyrimidine 
core tends to exert a profound influence in conferring novel biological activities in these 
molecules (12–14). Pyrimidine and their fused derivatives play an essential role in several 
biological processes and have considerable chemical and pharmacological importance. In 
particular, pyrimidine nucleus can be found in a broad variety of antibacterial and antitu-
mor agents, as well as in agrochemical and veterinary products (15, 16). Some substituted 
pyrano[2,3-c]pyrazoles have been found to be effective antiplatelet molecules (17), which 
effect K+-induced calcium-dependent aortal contraction. Several pyrano[2,3-c]-pyrazol-4-
ones have demonstrated affinity toward A1 and A2a adenosine receptors (18). Also, 6-ami-
no-5-cyano-dihydro-pyrano[2,3-c]pyrazoles have been identified as a screening hit for 
human Chk1 kinase inhibitors (19). We herein report the use of 6-amino-3-methyl-4-(4-
florophenyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (1) as starting material for 
the synthesis of a new series of pyrazolopyranopyrimidines (2–6) and their derivatives 
11a,b, pyrazolopyranoquinoline (7) and pyrazolopyranotriazine (8).
eXPerimenTAl
All melting points were measured on an electrothermal 9100 series digital melting 
point apparatus (Shimadzu, Japan). microanalytical data were provided by a Vario ele-
mentar apparatus (Shimadzu, Japan). Elemental analyses of all compounds were within ± 
0.4 % of the theoretical values. Physicochemical data are given in Table I. The IR spectra 
(Kbr) were recorded on a Perkin elmer 1650 spectrometer (uSA). 1H spectra were recorded 
on a JeOl eX-300 and JeOl eCA-500 (Japan). Chemical shifts were expressed in ppm rela-
tive to Sime4 as internal standard in dmSO-d6 as a solvent. mass spectra were recorded on 
a 70 eV finnigan SSQ 7000 spectrometer (Thermo-instrument System incorporation, uSA) 
(Table ii). The purity of the compounds was checked on aluminium plates coated with 
silica gel (merck, Germany). Chemicals and solvents were purchased from Sigma-Aldrich 
(uSA). norfloxacin and fluconazole were supplied by Pasteur laboratory (Giza, egypt). 
Compound 1 was synthesized according to the reported procedure (20).
Syntheses
6-Amino-3-methyl-4-fluorophenyl-1,4-dihydro-pyrano[2,3-c]pyrazole-5-carbonitrile (1). – 
Ethyl-3-(2-carbamo-thioylhydrazineylidene)-butanoate (2.03 g, 10 mmol) was added into 
sodium ethoxide solution (20 ml) followed by 2-(4-flurobenzylidene)-malononitrile (1.71 g, 
10 mmol). The reaction mixture was heated under reflux for 6 h. The compound obtained 
was crystallized as yellow powder.
4-(4-Fluorophenyl)-5-imino-3-methyl-1,4-dihydropyrazolo[4’,3’:5,6]pyrano[2,3-d]pyri-
midin-6(5H)-amine (2). – Compound 1 (0.01 mol) was added to a mixture of triethylortho-
formate (0.01 mol) and acetic anhydride (20 ml), and the reaction mixture was refluxed for 
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5 h. The solvent was removed under reduced pressure. The separated solid was refluxed 
with hydrazine hydrate (0.01 mol) in absolute ethanol (50 ml). The reaction mixture was 
refluxed for 2 h, concentrated, cooled, and the solid product that separated out was filtered 
off and recrystallized as yellow powder.
4-(4-Substituted phenyl)-3-methyl-4,8-dihydropyrazolo[4’,3’:5,6]pyrano[2,3-d]pyrimidine 
5(1H)-ones (3a,b). General procedure. – A mixture of 1 (0.01 mol) and appropriate acid (formic 
and/or acetic acid) was refluxed. The solvent was removed under reduced pressure and the 
separated solid was recrystallized from appropriate solvent in a good yield to give 3a,b 
respectively.
N-[4-(4-fluorophenyl)-3-methyl-7-oxo-6-phenyl-4,6,7,8-tetrahydropyrazolo[4’,3’:5,6]pyrano-
[2,3-d]pyrimidine-5(1H)-ylidene]benzamide (4). – Phenyl isocyanate (0.01 mol) and triethyl-
amine (0.5 ml) were added to a solution of 1 (0.01 mol) in ethanol (20 ml). The reaction 
mixture was refluxed for 3 h, cooled and the resulting solid was filtered off and recrystal-
lized to give 4 as yellow powder.
N-[4-(4-fluorophenyl)-3-methyl-7-thioxo-1,4,7,8-tetrahydropyrazolo[4’,3’:5,6]pyrano[2,3-d] -
pyrimidine-5-yl]thiourea (5). – Ammonium thiocyanate (0.03 mol) was added to a solution of 
1 (0.01 mol) in acetic acid (15 ml) and the reaction mixture was refluxed for 10 h. The solid 
that separated upon cooling and dilution with water was filtered off and purified to give 
5 as pale brown powder.
4-(4-Fluorophenyl)-3-methyl-1,4-dihydropyrazolo[4’,3’:5,6]pyrano[2,3-d]pyrimidin5-amine 
(6). – Compound 1 (0.01 mol) was added to a mixture of formamide (10 ml), formic acid (5 
ml) and dimethylformamide (5 ml). The reaction mixture was refluxed for 12 h. The solid 
that separated on cooling was filtered off as pale yellow powder.
4-(4-Fluorophenyl)-3-methyl-1,4,6,7,8,9-hexahydropyrazolo[4’,3’:5,6]pyrano[2,3-b]quinolin-
5-amine (7). – Cyclohexanone (2.8 mmol) was added to a solution of 1 (2 mmol) in a mixture 
of dichloroethane/THf (2:1). After stirring for 5 min at room temperature, aluminum chlo-
ride (4 mmol) was added, and the mixture was heated under reflux for 2 h. The mixture 
was cooled to room temperature and aluminum chloride (4 mmol) was added. The mixture 
was refluxed 2 h. The solvent was removed under reduced pressure. An aqueous solution 
of sodium hydroxide (50 ml, 10 %) was added. After stirring for 30 min, the precipitate was 
filtered, washed twice with 25 ml of water and with 10 ml of ether, dried at room tem-
perature until constant mass, purified in 5 ml of acetonitrile, and filtered while hot as 
white powder.
4-Chloro-5-(4-f luorophenyl)-6-methyl-5,8-dihydro-pyrazolo[4’,3’:5,6]pyrano[2,3-d]
[1,2,3]-triazine (8). – A solution of sodium nitrite (11.4 mmol) in water (7 ml) was added for 
15 min to a suspension of the foregoing compound 1 (8.1 mmol) at 0–5 °C in concentrated 
hydrochloric acid (16 ml). The resulting mixture was stirred at 0 °C for further 40 min and 
then allowed to stand at room temperature overnight. The reaction mixture was quenched 
in water (100 ml). The precipitate was washed twice with 15 ml of water and dried under 
room temperature, purified in 2 ml of acetonitrile, and filtered while hot to give 8 as or-
ange powder.
5-(4-Fluorophenyl)-4-(pyrrolidine, morpholine, piperazine, and/or N-(methyl-piperazinyl)-6-
methyl-5,8-dihydropyrazolo[4’,3’:5,6]pyrano[2,3-d][1,2,3]triazines (9, 10a–c). General procedure. 
– Compound 8 (1 mmol) and the corresponding amine (5 mmol) were fused in a sand bath 
for 6 h. The mixture was cooled at room temperature and poured into ethanol (30 ml) 
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under stirring. When a precipitate was formed, it was filtered off, washed twice with 15 
ml of ethanol and twice with 8 ml of diethyl ether, and then dried at room temperature 
overnight.
5-(4-Fluorophenyl)-6-methyl-4-pyrrolidin-1-yl)-5,8-dihydropyrazolo[4’,3’:5,6]pyrano[2,3-
d]-[1,2,3]triazine (9) was obtained from 8 with pyrrole as pale yellow powder, 5-(4-fluoro-
phenyl-6-methyl-4-morpholin-4-yl)-5,8-dihydropyrazolo-[4’,3’:5,6]pyrano-[2,3-d][1,2,3]triazine 
(10a) was obtained from compound 8 with morpholine as yellow powder, 5-(4-fluorophenyl)-
6-methyl-4-piperazin-1-yl)-5,8-dihydropyrazolo[4’,3’:5,6]pyrano[2,3-d]-[1,2,3]triazine (10b) was 
obtained from 8 with piperazine as brown powder, and 5-(4-fluorophenyl)-6-methyl-4-meth-
ylpiperazin-1-yl)-5,8-dihydropyrazolo[4’,3’:5,6]pyrano [2,3-d][1,2,3]triazine (10c) was obtained 
from 8 with N-methylpiperazine as gray powder.
4-(4-Fluorophenyl)-N-[(1Z)-(4-substituted phenyl)methylene]-5-imino-3-methyl-1,4-dihy-
dro-pyrazolo[4’,3’:5,6]pyrano[2,3-d]pyrimidin-6(5H)-amine (11a,b). General procedure. – A mix-
ture of 2 (0.31 g, 1.0 mmol), with appropriate aldehyde (p-fluorobenzaldehyde or 4-me-
thoxy benzaldehyde) (10 mmol), piperidine (0.5 ml) and dioxane (30 ml) was refluxed for 
6 hours. The precipitate was filtered off and washed several times with cold etOH. The 
solid was recrystallized from the appropriate solvent.
4-(4-fluorophenyl)-N-[(1Z)-(4-fluorophenyl)methylene]-5-imino-3-methyl-1,4-dihy-
dro-pyrazolo[4’,3’:5,6]pyrano[2,3-d]pyrimidin-6(5H)-amine (11a) was obtained from 2 with 
p-flurobenzaldehyde as pale yellow powder, and 4-(4-fluorophenyl)-5-imino-N-[(1Z)-(4-
methoxyphenyl)methylene]-3-methyl-1,4-dihydro-pyrazolo[4’,3’:5,6]pyrano[2,3-d]pyrimi-
din-6(5H)-amine (11b) was obtained from 2 with 4-methoxy-benzaldehyde as pale brown 
powder
11-(4-Fluorophenyl)-2-(4-substituted phenyl)-10-methyl-8,11-dihydropyrazolo[4’,3’:5,6]pyra-
no-[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine (12a,b). General procedure. – Compounds 11a,b 
where to come with alumina-supported calcium hypochlorite Ca(OCl)2 /Al2O3 = 1:1, ground 
mixture, stirred overnight and the reaction mixture was quenched in water (50 ml).
2,11-bis(4-fluorophenyl)-10-methyl-8,11-dihydropyrazolo[4’,3’:5,6]pyrano[3,2-e][1,2,4] - 
-triazolo[1,5-c]pyrimidine (12a) was obtained from 11a as pale gray powder, while 
11-(4-fluorophenyl)-2-(4-methoxyphenyl)-10-methyl-8,11-dihydropyrazolo[4’,3’:5,6]pyrano-
[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine (12b) was obtained from 11b as pale yellow powder.
11-(4-Fluorophenyl)-10-methyl-8,11-dihydropyrazolo[4’,3’:5,6]pyrano[3,2-e][1,2,4]triazolo-
[1,5-c]pyrimidine-2(3H)-thione (13). – To a solution of 2 (0.31 g, 10 mmol in dry pyridine (30 
ml), CS2 (20 mmol) was added and the reaction mixture was heated under reflux for 8 h. 
After cooling, the reaction mixture was poured onto ice/HCl mixture and the solid that 
separated was washed with cold water and filtered off to give 13 as yellow powder.
2-[4-(4-Fluorophenyl)-5-imino-3-methyl-1,4-dihydropyrazolo[4’,3’:5,6]pyrano[2,3-d]pyrimi-
din-6(5H)-yl]-1H-isoindole-1,3(2H)-dione (14). – To a solution of 2 (0.31 g, 10 mmol) in n-buOH, 
10 mmol of phathalic acid anhydride was added. The reaction mixture was left overnight 
and the solid that formed (14) was collected as pale brown powder.
(2z)-2-{[4-(4-fluorophenyl)-5-imino-3-methyl-1,4-dihydropyrazolo[4’,3’:5,6]-pyrano[2,3-d]
pyrimidin-6(5H)-yl]imino}-1,2-dihydro-3H-indol-3-one (15). – A solution of 2 (0.31 g, 10 mmol) 
in dioxane (10 ml) was stirred with isatin (15 mmol) for 24 hours at room temperature. The 
product that separated out (15) as orange powder was filtered off.
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Pharmacological screening
Antimicrobial activity. – Antimicrobial activities of the newly synthesized compounds 
were tested in vitro for activity against the following bacteria: Gram-positive bacteria Strep-
tococcus lactis NCTC-1030, Staphylococcus aureus NCTC-4493, Enterococcus faecalis NCTC-
4737, Gram-negative bacteria Escherichia coli ATCC-1416, Pseudomonas aeruginosa ATCC- 
2642, Klebsiella pneumoniae ATCC-1081, and fungal strains Candida albicans ATCC- 14154, 
Aspergillus flavus ATCC-23554 and Ganoderma lucidum ATCC-33455. All microorganisms 
were purchased from the American Type Culture Collection (manassas, uSA). The newly 
synthesized compounds (2–15) were dissolved in dmSO and tested for antimicrobial ac-
tivity with the agar disk diffusion technique (21), using a 1-cm microplate-well diameter 
and a solution of 100 mg ml–1 of the test compound. Compound-impregnated disks were 
placed on an agar plate containing a standard suspension of microorganisms. The plate 
was incubated for 24 h at 37 °C. Diameters of the zones of inhibition were measured with 
calipers or automated scanners and were compared with those of the standards. norfloxa-
cin (0.16 mmol ml–1) and fluconazole (6.5 x 10–3 mmol ml–1) were used as reference drugs 
for antibacterial and antifungal activity, respectively.
for determination of minimum inhibitory concentrations (MIC) (22) by the serial plate 
dilution method, 5 mg of each test compound was dissolved in 1 ml of dimethylsulfoxide 
(dmSO) to prepare the stock solution. Serial dilutions were prepared from the stock solu-
tion. The plates were incubated at 37 °C for 24 h. MIC was the lowest concentration (mmol 
ml–1) of the test compound that resulted in no visible growth on the plates. dmSO was 
used as a solvent control to ensure that the solvent had no effect on bacterial growth. The 
results of antimicrobial activities are summarized in Tables I and II.
reSulTS And diSCuSSiOn
Chemistry
The bifunctional compound 1 was used for the synthesis of pyrazolopyranopyrimi-
dine derivatives by the reaction with different reagents. Thus, the treatment of 6-amino-3-
methyl-4-(substituted-phenyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (1), which 
is the starting material (23) for the synthesis of polycyclic fused ring systems, with tri-
ethylorthoformate followed by hydrazine hydrate afforded three fused rings, namely, 
4-(4-fluorophenyl)-5-imino-3-methyl-1,4-dihydropyrazolo[4’,3’:5,6]pyrano[2,3-d]pyrimi-
din-6(5H)-amine (2). Also, the reaction of 1 with formic acid and/or acetic acid afforded 
pyranopyrimidine derivatives 3a,b. In addition, the interaction of 1 with phenylisocyanate 
consumed two moles of the reagent to furnish N-[(5Z)-4-(4-fluorophenyl)-3-methyl-7-oxo -
-6-phenyl-4,6,7,8-tetrahydropyrazolo[4’,3’:5,6]-pyrano[2,3-d]pyrimidine-5(1H)-ylidene]ben-
zamide (4). Heating of 1 with ammonium thiocyanate in boiling acetic acid gave pyrano-
pyrimidinethione derivatives (5). The treatment of 1 with formamide in the presence of 
formic acid and dimethylformamide gave compound 6. The structure of 6 was confirmed 
via inspection of elemental analysis and spectral data. Its 1H nmr spectrum revealed d at 
5.00 (s, pyran-H), 7.19 (d, 2H, Ar-H), 7.80 (d, 2H, Ar-H), 8.10 (s, CH pyrimidine) and 10.29, 
11.60 ppm (2 nH). Compound 4-(4-fluorophenyl)-3-methyl-1,4,6,7,8,9-hexahy dro-
pyrazolo-[4’,3’:5,6]pyrano[2,3-b]quinolin-5-amine (7) was obtained in good yield (see 
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Table II. Spectral data of newly synthesized compounds 
Compd. ir (Kbr) (n max, cm–1) 
mS 
(m/z)
1H, 13C nmr (dmSO-d6)
(d, ppm)





2.20 (s, 3H, CH3), 4.94 (s, pyran-H), 7.23 (d, 2H, Ar-H), 7.90 (d, 2H, 
Ar-H), 10.24, 10.52 (2brs, D2O exchangeable-NH)
2 3370, 1615 mS 312 
(m+, 86 %)
2.17 (s, 3H, CH3), 5.05 (s, pyran-H), 7.23 (d, 2H, Ar-H), 7.72 (d, 2H, 
Ar-H), 8.01 (s, 1H, pyrimidine-CH). 10.05, 10.26 (2brs, D2O 
exchangeable-NH)




2.23 (s, 3H, CH3), 5.01 (s, pyran-H), 8.58 (1H, s, pyrimidine-CH), 
7.23 (d, 2H, Ar-H), 7.78 (d, 2H, Ar-H), 8.09 (s, 1H, pyrimidine-CH). 
10.20, 10.62 (2brs, D2O exchangeable-NH)




2.20 (s, 3H, CH3), 2.24 (s, 3H, CH3) 5.05 (s, pyran-H), 7.23 (d, 2H, 
Ar-H), 7.78 (d, 2H, Ar-H), 10.20, 10.62 (2brs, D2O exchangeable-NH)




2.20 (s, 3H, CH3), 4.99 (s, pyran-H), 6.90–7.01 (m, 5H, Ar-H), 7.37–7.90 
(m, 5H, Ar-H), 8.09 (d, 2H, Ar-H), 8.20 (d, 2H, Ar-H), 8.35 (s, 1H, 
pyrimidine-CH), 10.65, 11.53, 14.03, (3s, 3H, D2O exchangeable 3NH




2.23 (s, 3H, CH3), 4.95 (s, pyran-H), 7.23 (d, 2H, Ar-H), 7.90 (d, 2H, 
Ar-H), 10.24, 10.52, 11.43, 12.03, (4brs, D2O exchangeable-NH)
6 3370, 1622 mS 297 
(m+, 80 %)
2.19 (s, 3H, CH3), 5.00 (s, pyran-H), 7.19 (d, 2H, Ar-H), 7.8 0 (d, 2H, 
Ar-H), 8.10 (s, 1H, pyrimidine-CH), 10.29, 11.60 (2brs, D2O 
exchangeable-NH)
7 3320, 3205 mS 350 
(m+, 75 %)
1.76 (m, 4H, 2CH2), 2.20 (s, 3H, CH3), 2.45 (m, 2H, CH2), 2.70 (m, 
2H, CH2), 4.98 (s, pyran-H), 6.22 (s, 2H, NH2), 7.20 (d, 2H, Ar-H), 
7.80 (d, 2H, Ar-H), 10.22, (br, 1NH, D2O exchangeable)
8 3310,1622 mS 317 
(m+, 70 %)
2.21 (s, 3H, CH3), 5.12 (s, pyran-H), 7.15 (d, 2H, Ar-H), 7.60 (d, 2H, 
Ar-H), 10.35 (br, 1NH, D2O exchangeable)
9 3315 mS 352 
(m+, 53 %)
2.19 (s, 3H, CH3), 2.58 (m, 4H, 2CH2), 3.56 (m, 2H, CH2), 3.80 (m, 
2H, CH2), 4.98 (s, pyran-H), 7.21 (d, 2H, Ar-H), 7.80 (d, 2H, Ar-H), 
10.34, (br, 1NH, D2O exchangeable)
10a 3310 mS 368 
(m+, 65 %)
2.15 (s, 3H, CH3), 3.47 (m, 4H, 2CH2), 3.76 (m, 4H, 2CH2), 5.01 
(s, pyran-H), 7.15 (d, 2H, Ar-H), 7.74 (d, 2H, Ar-H), 10.40 (br, 1NH, 
D2O exchangeable)
10b 3315 mS 367 
(m+, 70 %)
2.17 (s, 3H, CH3), 2.48 (brs, 4H, piperazinyl 2NCH2), 3.29 (brs, 4H, 
piperazinyl 2NCH2), 5.05 (s, pyran-H), 7.08 (d, 2H, Ar-H), 7.68 (d, 
2H, Ar-H), 10.25, (br, 1NH, D2O exchangeable)
10c 3312 mS 381 
(m+, 67 %)
2.13 (s, 3H, CH3), 2.33 (s, 3H, piperazinyl NCH3), 2.53 (brs, 4H, 
piperazinyl 2NCH2), 3.36 (brs, 4H, piperazinyl 2NCH2), 5.00 (s, 
pyran-H), 7.01 (d, 2H, Ar-H), 7.80 (d, 2H, Ar-H), 10.09, (br, 1NH, 
D2O exchangeable)
11a 3325, 1625 mS 418 
(m+, 90 %)
2.30 (s, 3H, CH3), 5.10 (s, pyran-H), 6.80 (s, 2H, NH2), 7.25 (d, 2H, 
Ar-H), 7.80 (d, 2H, Ar-H), 7.57 (d, 2H, Ar-H), 7.94 (d, 2H, Ar-H), 
8.39 (s, 1H, pyrimidine-CH), 8.90 (s, 1H, N=CH), 10.09 (br, 1NH, 
D2O exchangeable)
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Scheme 1) by the friedlander reaction on pyranopyrazole 1 (24) by heating compound 1 
with cyclohexanone in dichloroethane, aluminium chloride and THf as solvent and reflux 
of reaction mixture for 15 h.
Compd. ir (Kbr) (n max, cm–1) 
mS 
(m/z)
1H, 13C nmr (dmSO-d6)
(d, ppm)
11b 3315,1615 mS) 430 
(m+, 85 %)
2.35 (s, 3H, CH3), 3.59 (s, 3H, OCH3), 5.06 (s, pyran-H), 6.82 (s, 1H, 
nH), 7.30 (d, 2H, Ar-H), 7.78 (d, 2H, Ar-H), 7.60 (d, 2H, Ar-H), 7.99 
(d, 2H, Ar-H), 8.35 (s, 1H, pyrimidine-CH), 9.25 (s, 1H, N=CH), 
10.05 (br, 1NH, D2O exchangeable)
12a 3320, 1630 (mS) 416 
(m+, 90 %)
2.22 (s, 3H, CH3), 5.10 (s, pyran-H), 7.20 (d, 2H, Ar-H), 7.85 (d, 2H, 
Ar-H), 7.48 (d, 2H, Ar-H), 8.00 (d, 2H, Ar-H), 8.30 (s, 1H, pyrimi-
dine-CH) 10.20 (br, 1NH, D2O exchangeable)
12b 3318, 1625 (mS) 428 
(m+, 90 %)
2.20 (s, 3H, CH3), 3.60 (s, 3H, OCH3), 5.05 (s, pyran-H), 7.22 (d, 2H, 
Ar-H), 7.87 (d, 2H, Ar-H), 7.44 (d, 2H, Ar-H), 8.05 (d, 2H, Ar-H), 
8.35 (s, 1H, pyrimidine-CH), 10.23 (br, 1NH, D2O exchangeable)
13 1453, 3400 (mS) 353 
(m+, 60 %)
2.19 (s, 3H, CH3), 5.05 (s, pyran-H), 7.30 (d, 2H, Ar-H), 7.80 (d, 2H, 
Ar-H), 8.15 (s, 1H, pyrimidine-CH), 10.90, 11.52 (2brs, 2H, D2O 
exchangeable-2NH)




2.30 (s, 3H, CH3), 4.98 (s, pyran-H), 7.14–7.20 (m, 2H, Ar-H and 
pyrimidine-H), 7.54–7.81 (m, 3H, Ar-H), 7.99 (d, 2H, Ar-H), 8.10 
(d, 2H, Ar-H), 9.05, 10.11 (2brs, 2H, D2O exchangeable-NH)




2.20 (s, 3H, CH3), 4.95 (s, pyran-H), 7.37–7.86 (m, 4H, Ar-H), 8.07 
(d, 2H, Ar-H), 8.16 (d, 2H, Ar-H), 8.30 (s, 1H, pyrimidine-CH), 
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Amino-cyanopyranopyrazole 1 could also be used to synthesize pyrazolopyranotri-
azine 8. The 4- chlorotriazine ring was prepared via a one-pot process of diazotation and 
dediazo-chlorination. The reactivity of chlorine atom in 4-chloro-5-(4-fluorophenyl)-6-
methyl-5,8-dihydropyrazolo-[4’,3’:5,6]pyrano[2,3-d][1,2,3]triazine (8) appeared when com-
pound 8 was subject to the action of secondary amine, namely, pyrole, morpholine, pi-
perazine and N-methylpiperazine. The chlorine atom was displaced to form the 
corresponding compounds 9 and 10a–c, respectively (Scheme 2).
According to the literature (25, 26), compounds having azomethine linkage exhibit 
E/Z geometrical isomerism around C=N double bond and can exist as cis/trans amide con-
formers (26). moreover, hydrazones were proven to exist in higher percentage in dmSO-d6 
solution in the form of geometrical E isomers. Thus, compound 2 on treatment with the 
appropriate aromatic aldehyde, namely p-fluorobenzaldehyde/anisaldehyde, by refluxing 
with ethanol in the presence of a catalytic amount of piperidine gave 4-(4-fluorophenyl)-
N-[(1E)-(4-substitutedphenyl)-methyl-ene]-5-imino-3-methyl-1,4-dihydropyrazolo[4’,3’:5,6]
pyrano[2,3-d]pyrimidin-6(5H)-amines (11a,b). Also, nmr spectra of compounds 11 re-
corded in dmSO-d6 solution revealed that all compounds existed as E geometrical isomers. 
Oxidative cyclization of the resultant hydrazone derivatives 11a,b to 12a,b was achieved 
by using alumina-supported calcium hypochlorite (Ca(OCl)2/Al2O3 = 1:1, ground mixture) 







































0    5– oC
910a c–
a, X = O
b, X = NH
c, X = N-CH3
Scheme 2
for instance, a maximum yield of 73 % for 12a and 75 % for 12b in 2 h was achieved 
with the 1:3 molar ratio of hydrazone to calcium hypochlorite. The use of alumina-sup-
ported calcium hypochlorite as a heterogeneous oxidant in this reaction has the advantage 
of an enhanced reaction rate and yield (see Scheme 3).
furthermore, the hydrazide derivative 2 reacted with carbon disulfide and naOH in 
ethanol to afford 11-(4-fluorophenyl)-10-methyl-8,11-dihydropyrazolo[4’,3’:5,6]pyrano[3,2-e]
[1,2,4]tria-zolo[1,5-c]pyrimidine-2(3H)-thione (13) (Scheme 3).
in the present work, we wish to point out the reaction of hydrazino derivative 2 with 
phthalic anhydride. When compound 2 with phthalic anhydride in an oil bath, it yielded 
2-phthalimidoamino derivative 14. The reaction took place via acylation of hydrazino moi-
ety by phthalic anhydride, followed by ring closure to give the desired product. On the 
other hand, stirring of compound 2 with isatin at room temperature yielded compound 15 
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(Scheme 4). The structure of the resultant compound was fully established by spectral 
data, which included IR, 1H nmr and mS spectra. The 1H nmr spectra of compound 15 
revealed signals at d: 2.20 (s, 3H, CH3), 4.95 (s, pyran-H), 7.37–7.86 (m, 4H, Ar-H), 8.07 (d, 2H, 
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Antimicrobial screening and SAR
The minimum inhibitory concentration values (MICs) against different Gram-positive, 
Gram-negative bacteria and fungi were tested. The investigations showed significant in-
hibitory effects against bacteria with the majority of the compounds with MIC values of 
1–21 mmol ml–1 (Table III). The antibacterial data indicated that compounds 2, 3a,b, 4, 5, 6, 
11a,b, 13 and 14 displayed good activity against all tested bacteria. This activity can be at-
tributed to the presence of pyrimidine moiety. Compound 2 comprised iminopyrimidine 
with amino group attached at N-3, compounds 3a,b are pyrimidone derivatives, while com-
pounds 4, 5 are 6 are 4-amino pyrimidine and pyrimidine thione derivatives. Compounds 
11a,b contain N-hydrazonyl, 13 triazolo thione and 14 N-isoindol dione pyrimidine moi-
eties. Evaluation of the antibacterial activity of synthesized compounds 7 and 8 revealed 
that compounds were effective against all tested bacteria due to the presence of tetrahydro-
quinoline moiety in 7 and 4-chlorotriazine in 8. Regarding the antibacterial activities, pyr-
azolopyranotriazine derivatives 9 and 10a–c were the most active compounds; their MIC 
values were 1–5 mmol ml–1 against Gram-positive and 3–8 mmol ml–1 against Gram-nega-
tive bacteria compared to the standard drug norfloxacin with respective MICs of 2–3 and 
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4–5 mmol ml–1. The antimicrobial activity of compound 10c comprising N-methylpipera-
zine attached to the triazine moiety at position 4 exhibited the higher activity against S. 
lactis, E. faecalis, E. coli and K. pneumoniae, but was equipotent against S. aureus and P. aeu-
roginosa compared to norfloxacin, whereas compounds 9 and 10a,b showed promising ac-
tivity against bacteria which were equal or nearly close to MIC of norfloxacin. The activity 
of the latter compounds can be attributed to the presence of pyrolyl in 9, morpholinyl in 10a 
and piperazinyl moiety in 10b, attached to the pyranotriazine, which increased the antimi-
crobial activity against Gram-positive and Gram-negative bacteria.
On the other hand compound 12a,b displayed antibacterial activity with MIC equal 
or nearly close to MIC of norfloxacin, This is attributed to the presence of 4-fluoro sub-
stituent in the phenyl ring attached to [1,2,4]triazole in compound 12a, while compound 
12b had 4-methoxyphenyl. Among the synthesized hydrazone derivatives, compound 15 
displayed antibacterial activity comparable to that of norfloxacin against E. faecalis, E. coli 
and P. aeuroginosa, and was equal or nearly close to MIC of norfloxacin against S. lactis, S. 
aureus and K. pneumoniae. This can be attributed to the presence of the indol-3-one attached 
to N-pyrimidinyl derivative.
Table III. Minimal inhibitory concentration (MIC, mmol mL–1) of the synthesized compounds against bacteria
Compd.
microorganism
 S. lactis S. aureus E. faecalis E. coli P. aeuroginosa K. pneumoniae
2   9 12 17 20 20 21
3a 14 12 14 18 14 14
3b 15 16 15 16 17 14
4 14 13 17 17 17 18
5 14 12 14 18 14 14
6 12 14 15 15 18 18
7 10 10 12 15 14 16
8   8   8   8 10 11 11
9   3   2   3   5   7   5
10a   4   3   5   4   4   3
10b   5   3   2   6   6   8
10c   1   2   2   3   5   3
11a 12 14 15 15 18 18
11b 10 15 17 14 15 15
12a   2   3   3   5   6   5
12b   5   4   5   8   6   8
13 11 10 10 11 12 16
14 12 13 13 10 12 14
15   3   3   2   3   4   4
norfloxacin   2   2   3   4   5   4
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Antifungal screening showed that most of the tested compounds possessed antifun-
gal activity against all fungal strains (Table iV). Compound 5 exhibited higher activity 
aganist C. albicans and G.lucidum and was equal to MIC of fluconazole against A. flavus This 
may be is attributed to the presence of an intact thiourea nH-(C=S)-nH grouping attached 
to the thioxopyrimidine. On the other hand, compounds 8, 9, 10a,b, 12a,b, 14, and 15 re-
vealed good antifungal activity against the examined fungi compared to fluconazole as 
reference antifungal, while the other compounds (2, 3a,b, 4, 6, 7, 10c, 11a,b and 13) exhib-
ited moderate antifungal activities.
COnCluSiOnS
The objective of the present study was to synthesize and investigate the antimicrobial 
activity of some novel pyrazolopyranopyrimidine, pyrazolopyranotriazine and pyrazolo-
pyranotriazolo- pyrimidine derivatives. Compound 5-(4-fluorophenyl)-6-methyl-4-meth-
ylpiperazin-1-yl)-5,8-dihydropyrazolo[4’,3’:5,6]pyrano[2,3-d][1,2,3]triazine (10c) was found 
to have the most potent antibacterial activity slightly higher than that of norfloxacine. On 
Table IV. Minimal inhibitory concentration (MIC, mmol mL–1) of the synthesized compounds against fungi
Compd.
microorganism
 C. albicans A. flavus G. lucidum
2 27 22 21
3a 20 17 22
3b 23 24 21
4 21 24 26
5 2 2 2
6 18 24 22
7 17 17 21
8 14 12 12
9 11 12 14
10a 13 17 14
10b 8 7 8
10c 25 27 22
11a 24 21 23
11b 22 24 18
12a 10 10 14
12b 14 12 14
13 17 20 17
14 7 6 6
15 11 7 14
fluconazole 3 2 3
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the other hand, compound N-[4-(4-fluoro-phenyl)-3-methyl-7-thioxo-1,4,7,8-tetrahydropyr-
azolo[4’,3’:5,6]pyrano[2,3-d]-pyrimidine-5-yl]thiourea (5) exhibited higher potency of anti-
fungal activity than fluconazole.
Acknowledgements. – The authors are grateful to the micro-analytical unit, Cairo uni-
versity, egypt, for micro-analytical data, ir, nmr and mass spectra. The authors are also 
grateful to the fermentation biotechnology and Applied microbiology (ferm-bAm) Cen-
ter, Al-Azhar university, faculty of Science, Cairo, egypt. The authors extend their sincere 
appreciation to the deanship of Scientific research at the Al-imam mohammad ibn Saud 
islamic university for its funding of this research through the research Group Project no. 
341212.
referenCeS
  1.  A. b. A. el-Gazzar and H. n. Hafez, Synthesis of 4-substituted pyrido[2,3-d]pyrimidin-4(1H)-one 
as analgesic and anti-inflammatory agents, Bioorg. Med. Chem. Lett. 19 (2009) 3392–3397; DOI: 
10.1016/j.bmcl.2009.05.044.
  2.  f. m. A. el-Taweel, m. A. Sofan, m. A. mashaly, m. A. Hanna and A. A. elagamey, Synthesis of 
some new pyranoquinoline, pyridine and pyrone derivatives, Pharmazie 45 (1990) 671–673; DOI: 
10.1002/chin.199149187.
  3.  A. m. el-Agrody, m. S. Abd el-latif, n. A. el- Hady, A. H. fakery and A. H. bedair, Heteroaroma-
tization with 4-hydroxycoumarin Part II: Synthesis of some new pyrano[2,3-d]-pyrimidines, 
[1,2,4]triazolo[1,5-c]pyrimidines and pyrimido[1,6-b][1,2,4]triazine derivatives, Molecules 6 (2001) 
519–527; DOI: 10.3390/60600519.
  4.  A. H. bedair, n. A. el-Haddy, m. S. Abd el-latif, A. H. fakery and A. m. el-Agrody, 4- Hydroxy-
coumarin in heterocyclic synthesis. Part III: Synthesis of some new pyrano[2,3-d][1,2,4]triazolo[1,5-
c]pyrimidine and pyrimido[1,6-b][1,2,4]triazine derivatives, Farmaco 55 (2000) 708–714; DOI: 
10.1016/S0014-827X(00)00097-5.
  5.  A. m. el-Agrody, m. H. el-Hakim, m. S. Abd el-latif, A. H. fakery, e. m. el-sayed and K. A. el-
Ghareab, Synthesis of pyrano[2,3-d]pyrimidine and pyrano[3,2-e][1,2,4]triazolo[2,3-c] pyrimidine 
derivatives with promising antibacterial activities, Acta Pharm. 50 (2000) 111–120.
  6.  A. G. martinez and l. J. marco, friedlander reaction on 2-amino-3-cyano-4H-pyrans, synthesis of 
derivatives of 4H-pyran[2,3-b]quinoline, new tacrine analogues, Bioorg. Med. Chem. Lett. 7 (1997) 
3165–3170; DOI: 10.1016/S0960-894X(97)10165-2.
  7.  f. eiden and f. denk, Synthesis and CnS activity of pyrane derivatives: 6,8-dioxabicyclo(3,2,1)
octanes, Arch. Pharm. (Weinheim) 324 (1991) 353–354.
  8.  C. P. dell and C. W. Smith, Antiproliferative derivatives of 4H-naphtho[1,2-b]pyran and process 
for their preparation, Eur. Pat. 537, 94, 9 21 Apr 1993; ref. Chem. Abstr. 119 (1993) 139102d.
  9.  f. m. Abdelrazek, P. metz, n. H. metwally and S. f. el-mahrouky, Synthesis and molluscicidal 
activity of new cinnoline and pyrano[2,3-c]pyrazole derivatives, Arch. Pharm. Chem. Life Sci. 339 
(2006) 456–460.
10.  G. bianchi and A. Tava, Synthesis of (2R)(+)-2,3-dihydro-2,6-dimethyl-4H-pyran-4-one, a homo-
logue of pheromones of a species in the hepialidae family, Agr. Biol. Chem. 51 (1987) 2001–2002; 
DOI: 10.1271/bbb1961.51.2001.
11.  K. noda, A. nakagawa, Y. nakajima and H. ide, Pyrido[2,3-d]-s-triazolo[4,3-c]pyrimidine deriva-
tives, Japan Kokai 7785, 194, 15 Jul 1977; ref. Chem. Abstr. 88 (1978) P50908q.
412
H. N. Hafez et al.: facile heterocyclic synthesis and antimicrobial activity of polysubstituted and condensed pyrazolopyrano-
pyrimidine and pyrazolopyranotriazine derivatives, Acta Pharm. 65 (2015) 399–412.
 
12.  H. n. Hafez, H. A. S. Abbas and A. b. A. el-Gazzar, Synthesis and evaluation of analgesic, anti-
inflammatory and ulcerogenic activities of some triazolo- and 2-pyrazolyl-pyrido[2,3-d]-pyrimi-
dines, Acta. Pharm. 58 (2008) 359–378; DOI: 10.2478/v10007-008-0024-1.
13.  A. b. A. el-Gazzar, H. A. r. Hossein and H. n. Hafez, Synthesis and biological evaluation of 
thieno[2,3-d]pyrimidines derivatives as anti-inflammatory, analgesic and ulcerogenic activity, 
Acta. Pharm. 57 (2007) 395–411; DOI: 10.2478/v10007-007-0032-6.
14.  A. b. A. el-Gazzar, H. n. Hafez and G. m. nawwar, new acyclic nucleosides analogues as poten-
tial analgesic, anti-inflammatory, anti-oxidant and anti-microbial derived from pyrimido[4,5-b]
quinolines, Eur. Med. Chem. 44 (2009) 1427–1436; DOI: 10.1016/j.ejmech. 2008.09.030.
15.  l. P. Prikazchikova, b. m. Khutova, i. f. Vladimirtsev, i. V. boldyrev and n. i. zhuravskaya, stim-
ulating activity of mono- and diketone pyrimidine derivatives, Fiziol. Akt. Veshchestva 7 (1975) 
84–87; ref. Chem. Abstr. 83 (1975) 127346m.
16.  d. J. brown, Pyrimidines and Their Benzo Derivatives, in Comprehensive Heterocyclic Chemistry (Eds. 
A. r. Katritzky and C. W. rees), Vol. 3, Pergamon Press, Oxford 1984, p. 443.
17.  S. m. Yu, S. C. Kuo, l. J. Huang, S. S. m. Sun, T. f. Huang and C. m. Teng, Vasorelaxation of rat 
thoracic aorta caused by two Ca2+-channel blockers, HA-22 and HA-23, J. Pharm. Pharmacol. 44 
(1992) 667–671; DOI: 10.1111/j.2042-7158.1992.tb05491.x.
18.  d. Catarzi, l. Cecchi, V. Colotta, G. filacchioni, C. martini, P. Tacchi and A. lucacchini, Tricyclic 
heteroaromatic systems. Synthesis and A1 and A2a adenosine binding activities of some 1-aryl-
1,4-dihydro-3-methyl[1]benzopyrano[2,3-c]pyrazol-4-ones, 1-aryl-4,9-dihydro-3-methyl-1H-
pyrazolo[3,4-b]quinolin-4-ones, and 1-aryl-1H-imidazo[4,5-b]quinoxalines, J. Med. Chem. 38 (1995) 
1330–1336.
19.  n. foloppe, l. m. fisher, r. Howes, A. Potter, A. G. S. robertson and A. e. Surgenor, identification 
of chemically diverse Chk1 inhibitors by receptor-based virtual screening, Bioorg. Med. Chem. 14 
(14) (2006) 4792–4802; DOI: 10.1016/j.bmc.2006.03.021.
20.  H. m. Al-matar, K. d. Khalil, A. Y. Adam and m. H. elnagdi, Green one pot solvent-free synthesis 
of pyrano[2,3-c]pyrazoles and pyrazolo[1,5-a]pyrimidines, Molecules 15 (2010) 6619–6629; DOI: 
10.3390/molecules15096619.
21.  S. r. Jain and A. Kar, The antibacterial activity of some essential oils and their combination, 
Planta Med. 20 (1971) 118–123; DOI: 10.1055/s-0028-109967.
22.  H. naeimi, z. S. nazifi, S. m. Amininezhad and m. Amouheidari, Synthesis, characterization and 
in vitro antimicrobial activity of some new Schiff bases and their complexes, J. Antibiot. 66 (2013) 
687–689; DOI: 10.1038/ja.2013.73.
23.  m. b. madhusudana reddy, V. P. Jayashankara and m. A. Pasha, Glycine-catalyzed efficient syn-
thesis of pyranopyrazoles via one-pot multicomponent reaction, Synth. Commun. 40 (2010) 2930–
2934; DOI: 10.1080/00397910903340686.
24.  d. Thomae, G. Kirsch and P. Seck, Synthesis of selenophene analogues of the tacrine series: com-
parison of classical route and microwave irradiation, Synthesis 10 (2008) 1600–1606; DOI: 10.1055/s-
2008-1067001.
25.  n. Galic, b. Peric, b. Kojic-Prodic and z. Cimerman, Structural and spectroscopic characteristics 
of aroylhydrazones derived from nicotinic acid hydrazide, J. Mol. Struct. 559 (2001) 187–194; DOI: 
10.10.1016/S0022-2860(00)00703-1.
26.  V. Klimesova, l. zahajska, K. Waisser, J. Kaustova and u. mollmann, Synthesis and antimycobac-
terial activity of 1, 2, 4-triazole 3-benzylsulfanyl derivatives, Farmaco 59 (2004) 279–288; DOI: 
10.1016/j.farmac.2004.01.006.
